150 related articles for article (PubMed ID: 38055066)
21. Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study.
Garcia JM; Friend J; Allen S
Support Care Cancer; 2013 Jan; 21(1):129-37. PubMed ID: 22699302
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of systemic hemato-immunological indices in uterine cervical cancer: A systemic review, meta-analysis, and meta-regression of observational studies.
Han X; Liu S; Yang G; Hosseinifard H; Imani S; Yang L; Maghsoudloo M; Fu S; Wen Q; Liu Q
Gynecol Oncol; 2021 Jan; 160(1):351-360. PubMed ID: 33092868
[TBL] [Abstract][Full Text] [Related]
23. Anamorelin for patients with cancer cachexia: an integrated analysis of two phase 2, randomised, placebo-controlled, double-blind trials.
Garcia JM; Boccia RV; Graham CD; Yan Y; Duus EM; Allen S; Friend J
Lancet Oncol; 2015 Jan; 16(1):108-16. PubMed ID: 25524795
[TBL] [Abstract][Full Text] [Related]
24. Anamorelin hydrochloride for the treatment of cancer-anorexia-cachexia in NSCLC.
Zhang H; Garcia JM
Expert Opin Pharmacother; 2015 Jun; 16(8):1245-53. PubMed ID: 25945893
[TBL] [Abstract][Full Text] [Related]
25. Predictors of efficacy of anamorelin in patients with non‑small cell lung cancer and cachexia: A retrospective study.
Ishioka Y; Tanaka H; Makiguchi T; Fujishima S; Nunomura Y; Sakamoto H; Shiratori T; Taima K; Tasaka S
Oncol Lett; 2024 Jan; 27(1):22. PubMed ID: 38058465
[TBL] [Abstract][Full Text] [Related]
26. A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in advanced gastrointestinal cancer patients with cancer cachexia.
Hamauchi S; Furuse J; Takano T; Munemoto Y; Furuya K; Baba H; Takeuchi M; Choda Y; Higashiguchi T; Naito T; Muro K; Takayama K; Oyama S; Takiguchi T; Komura N; Tamura K
Cancer; 2019 Dec; 125(23):4294-4302. PubMed ID: 31415709
[TBL] [Abstract][Full Text] [Related]
27. The Predictive Value of Preoperative High-Sensitive C-Reactive Protein/Albumin Ratio in Systemic Inflammatory Response Syndrome After Percutaneous Nephrolithotomy.
Xu H; Hu L; Wei X; Niu J; Gao Y; He J; Hou J
J Endourol; 2019 Jan; 33(1):1-8. PubMed ID: 30430854
[TBL] [Abstract][Full Text] [Related]
28. Anamorelin for cancer anorexia-cachexia syndrome: a systematic review and meta-analysis.
Bai Y; Hu Y; Zhao Y; Yu X; Xu J; Hua Z; Zhao Z
Support Care Cancer; 2017 May; 25(5):1651-1659. PubMed ID: 28074289
[TBL] [Abstract][Full Text] [Related]
29. Validation and clinical usefulness of pre- and postoperative systemic inflammatory parameters as prognostic markers in patients with potentially resectable pancreatic cancer.
Hoshimoto S; Hishinuma S; Shirakawa H; Tomikawa M; Ozawa I; Ogata Y
Pancreatology; 2020 Mar; 20(2):239-246. PubMed ID: 31862230
[TBL] [Abstract][Full Text] [Related]
30. Predictive values of the postoperative neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio for the diagnosis of early periprosthetic joint infections: a preliminary study.
Zhao G; Chen J; Wang J; Wang S; Xia J; Wei Y; Wu J; Huang G; Chen F; Shi J; Lyu J; Liu C; Huang X
J Orthop Surg Res; 2020 Nov; 15(1):571. PubMed ID: 33256763
[TBL] [Abstract][Full Text] [Related]
31. Inflammation-based prognostic scoring system for predicting the prognosis of advanced small cell lung cancer patients receiving anlotinib monotherapy.
Chen T; Tang M; Xu X; Liang G; Xiang Z; Lu Y; Wang C; Shen W
J Clin Lab Anal; 2022 Dec; 36(12):e24772. PubMed ID: 36441595
[TBL] [Abstract][Full Text] [Related]
32. Lymphocyte-to-Monocyte Ratio and Prognostic Nutritional Index Predict Poor Prognosis in Patients on Chemotherapy for Unresectable Pancreatic Cancer.
Shimizu T; Taniguchi K; Asakuma M; Tomioka A; Inoue Y; Komeda K; Hirokawa F; Uchiyama K
Anticancer Res; 2019 Apr; 39(4):2169-2176. PubMed ID: 30952764
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of combined preoperative platelet-to-lymphocyte ratio and lymphocyte-to-monocyte ratio in patients undergoing surgery with stage IB non-small-cell lung cancer.
Chen Y; Wang W; Zhang X; Yu X; Xi K; Wen Y; Wang G; Feng X; Zhang L
Cancer Manag Res; 2018; 10():5411-5422. PubMed ID: 30519089
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of Anamorelin, a Novel Non-Peptide Ghrelin Analogue, in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) and Cachexia-Review and Expert Opinion.
Currow DC; Maddocks M; Cella D; Muscaritoli M
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30400622
[TBL] [Abstract][Full Text] [Related]
35. Neutrophil-to-lymphocyte Ratio, Platelet-to-lymphocyte Ratio, C-reactive Protein to Albumin Ratio, and Albumin to Fibrinogen Ratio in Axial Spondyloarthritis: A Monocentric Study.
Slouma M; Rahmouni S; Dhahri R; Gharsallah I; Metoui L; Louzir B
Curr Rheumatol Rev; 2021; 17(3):312-317. PubMed ID: 33357182
[TBL] [Abstract][Full Text] [Related]
36. An overview of anamorelin as a treatment option for cancer-associated anorexia and cachexia.
Fonseca GWPD; von Haehling S
Expert Opin Pharmacother; 2021 May; 22(7):889-895. PubMed ID: 33491505
[TBL] [Abstract][Full Text] [Related]
37. Prognostic Value of Inflammatory Biomarkers in Patients with Severe COVID-19: A Single-Center Retrospective Study.
Açıksarı G; Koçak M; Çağ Y; Altunal LN; Atıcı A; Çelik FB; Bölen F; Açıksarı K; Çalışkan M
Biomark Insights; 2021; 16():11772719211027022. PubMed ID: 34248354
[TBL] [Abstract][Full Text] [Related]
38. Prognostic Value of Neutrophil:Lymphocyte and Platelet:Lymphocyte Ratios for 28-Day Mortality of Patients with AECOPD.
Luo Z; Zhang W; Chen L; Xu N
Int J Gen Med; 2021; 14():2839-2848. PubMed ID: 34211292
[TBL] [Abstract][Full Text] [Related]
39. Neutrophil : lymphocyte ratio is associated with disease severity and mortality in patients with Stevens-Johnson syndrome/toxic epidermal necrolysis.
Wang Q; Lan YP; Qi B; Yin L; Zhang LX; Liu W
J Dermatol; 2021 Sep; 48(9):1394-1400. PubMed ID: 34060656
[TBL] [Abstract][Full Text] [Related]
40. Anamorelin for advanced non-small-cell lung cancer with cachexia: Systematic review and meta-analysis.
Nishie K; Yamamoto S; Nagata C; Koizumi T; Hanaoka M
Lung Cancer; 2017 Oct; 112():25-34. PubMed ID: 29191597
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
